IntegraGen, a developer and marker of molecular diagnostic testing in oncology and autism, has entered into an agreement with Pfizer that provides Pfizer access to evaluate the company’s proprietary molecular signature for hepatocellular carcinoma. The 56-gene molecular signature covered by the agreement is intended to predict the clinical prognosis of patients with hepatocellular carcinoma and subcategorize patients into six separate classifications based on the molecular characteristics of their liver tumors.
Bernard Courtieu, IntegraGen CEO, said, “The use of our molecular signature may help to identify specific patient populations who would benefit from Pfizer’s experimental compounds, if approved by regulatory authorities.”
